Cooperative Study Group for Autoimmune Disease Prevention

The summary for the Cooperative Study Group for Autoimmune Disease Prevention grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Cooperative Study Group for Autoimmune Disease Prevention: Single institutions or consortia of institutions are invited to participate in a cooperative research group focusing on prevention of human autoimmune diseases, with an emphasis on type 1 diabetes. In FY 2006, the co-sponsoring NIH Institutes and the Juvenile Diabetes Research Foundation International (JDRFI) anticipate awarding a total of $4.5 million to fund four to six awards, using the single-project (U01) and multi-project (U19) cooperative agreement award mechanisms. Additional discretionary funds of approximately $2.5 million will be allocated to the Study Group to fund innovative collaborative, discovery-based, and/or pilot and feasibility projects consistent with the overall goal of autoimmune disease prevention. Eligible institutions include for-profit or non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units of State and local governments; or eligible agencies of the Feder! al government. Foreign institutions are not eligible to apply as the primary applicant institution in a multi-project application, but may submit a single-project application or enter into a consortium with a domestic institution as the primary applicant. This RFA will not support clinical trials or studies of global immunosuppressive therapies, and proposals for clinical trials may not be submitted in the initial application. Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his or her institution to develop an application as the Principal Investigator. A Principal Investigator may submit only one application. However, participation of a Principal Investigator as a project leader in multi-project applications (U19 mechanism) is allowed if there is no scientific overlap with the application submitted by the Principal Investigator. Applications must be prepared using the most current PHS 398 research! grant application instructions and forms, available at http://grants. nih.gov/grants/funding/phs398/phs398.html. For further assistance contact GrantsInfo, telephone (301) 435-0714, email: [email protected]. Telecommunications for the hearing impaired is available at: TTY 301-451-0088.